Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 6Central Nervous System Neoplasms 5Gliosarcoma 4Brain Neoplasms 4Glioma 3Astrocytoma 3Sarcoma 1Rectal Neoplasms 1Oligodendroglioma 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Melanoma 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Temozolomide 29Bevacizumab 12Radiotherapy 10Irinotecan 7Carboplatin 7Carmustine 5Magnetic Resonance Spectroscopy 4Filgrastim 4Cyclophosphamide 4Cisplatin 4Vincristine 3Thiotepa 3Surgical Procedures, Operative 3Peripheral Blood Stem Cell Transplantation 3Etoposide 3talampanel 2sargramostim 2antineoplaston AS 2-1 2antineoplaston A10 2abemaciclib 2Topotecan 2Thalidomide 2Tamoxifen 2Sunitinib 2Radiotherapy, Intensity-Modulated 2Procarbazine 2Immunoglobulin G 2Everolimus 2Drug Therapy 2Doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Oligodendroglioma × O(6)-benzylguanine × Clear all
NCT00389090 2012-02-09

A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma

Keryx / AOI Pharmaceuticals, Inc.

Phase 2 Terminated
32 enrolled
CNS

Astrocytoma, Glioma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡